Overlooked & OverworkedMarch 2000
By Karin Granstrom Jordan, MD
Fibrosis, cirrhosis and alcohol
A characteristic feature of liver disease, regardless of its cause, is the increased deposition of collagen, the connective tissue protein. This increased collagen accumulation could result from enhanced collagen biosynthesis and/or decreased collagen breakdown. PPC appears to increase collagen breakdown by stimulating collagenase activity in hepatic stellate cells preventing the development of fibrosis and cirrhosis (Li J et al., 1992). Several studies have focused on PPC and its effect on collagen and fibrosis.
A baboon study (Lieber CS et al., 1994) confirmed earlier results (Lieber CS et al., 1990) showing that in the baboon, feeding of ethanol (a form of alcohol) results in hepatic fibrosis and cirrhosis even when associated with an adequate diet. This effect could be prevented by supplementing the diet with a 94-96% pure PPC preparation. None of the eight animals fed alcohol with PPC for up to 6.5 years had progression to fibrosis or cirrhosis as had 10 of 12 unsupplemented baboons, a highly significant difference. Another study (Ma X et al., 1996) revealed that PPC reduces hepatic fibrosis induced by either carbon tetrachloride or human albumin in rats, and that PPC not only prevents the development of fibrosis but accelerates the regression of pre-existing fibrosis. The study further suggested that the protective effect exerted by PPC against fibrosis is due, at least in part to increased collagen breakdown.
One of the ways PPC helps prevent liver damage from alcohol is by inhibiting an enzyme known as CYP 2E1. Chronic alcohol consumption raises levels of this enzyme, which is involved in the metabolism of alcohol. This leads to oxidative stress and acetaldehyde production, which stresses the antioxidant defense system and depletes glutathione. CYP 2E1 also furthers the production of toxic metabolites from common drugs such as acetaminophen and promotes carcinogenesis. CYP 2E1 inhibitors protect the liver from alcohol-induced damage, but drugs tested for this purpose have been too toxic for practical use. However it has recently been discovered that PPC significantly inhibits CYP 2E1 activity (Lieber CS, 1999; Aleynik MK et al., 1999), providing a potential nontoxic solution to this problem.
As we have seen, a key mechanism of PPC action is its antioxidant effect. Despite its rich content of polyunsaturated linoleic acid, PPC has been shown to effectively reduce oxidative stress caused by alcohol in the liver and pancreas, as well as in LDL cholesterol.
Newly published research (Aleynik SI, Leo MA, Takeshige U et al., 1999) identifies the constituent of PPC primarily responsible for its antioxidant effect. This constituent, DLPC, comprises 40-52% of PPC. The researchers found that the "remarkable" antioxidant effect of PPC on oxidative stress induced in hepatoma cells by arachidonic acid could be accounted for by the DLPC contained in it.
DLPC appears to be primarily responsible for many of the protective actions of PPC on the liver and pancreas. A new study demonstrates that DLPC stimulates the Kupffer cells of the liver to decrease production of the hepatotoxic tumor necrosis factor-a, while increasing production of the hepatoprotective interleukin-1b (Oneta CM et al., 1999). DLPC also appears to decrease activation of collagen-producing stellate cells in the liver, and to increase collagenase activity and thus collagen breakdown, asdiscussed above.
The benefits of protection
Modern living unfortunately involves daily exposure to substances that are toxic to our bodies, which can impose heavy stresses on the vital organs we have discussed. Therefore it is logical to think that all of us can benefit from some kind of support in maintaining the vitality of these organs. In particular, individuals with a substantial alcohol consumption, with obesity, diabetes or with high exposure to NSAIDs or environmental toxins have an even greater reason to take protective measures because of the documented risk of developing serious pathologies.
Knowing that conventional medicine has very little to offer in the prevention or early treatment of the disorders we have discussed, it seems wise to remember that prevention is the best cure. We are fortunate today to have access to a natural protective remedy that is safe, effective and without significant side effects.
And it is good to know that protection of the liver, pancreas and stomach is beneficial not only for these vital organs themselves, but for the overall health and vitality of our body.
Aleynik MK et al.: Polyenylphosphatidylcholine opposes the increase of cytochrome P-4502E1 by ethanol and corrects its iron-induced decrease. Alcohol Clin Exp Res 23(1):96-100, 1999
Aleynik SI, Leo MA, Aleynik MK et al.: Alcohol-induced pancreatic oxidative stress: Protection by phospholipid repletion. Free Radic Biol Med 26 (5/6): 609-619, 1999
Aleynik SI, Leo MA, Takeshige U et al.: Dilinoleoylphosphatidylcholine is the active antioxidant of polyenylphosphatidylcholine. J Investig Med 47(9):507-12, 1999
Anand BS et al.: Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol 94(7):1818-22, 1999
Barbagallo CM et al.: Lipoprotein profile and high-density lipoproteins: subfractions distribution in centenarians. Gerontology 44(2):106-10, 1998
Berson A et al.: Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114(4):764-74, 1998
Biagi PL et al.: The effect of dietary polyenylphosphatidylcholine on microsomal delta-6-desaturase activity, fatty acid composition, and microviscosity in rat liver under oxidative stress. J Nutr Biochem 4: 690-94, 1993
Braillon A et al.: Liver in obesity. Gut 26(2): 133-39, 1985
Day CP et al.: The biochemistry of alcohol-induced fatty liver. Biochim Biophys Acta 1215: 33-48, 1994
Dunjic BS et al.: Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic ulcers in rats. Scand J Gastroenterol; 28: 89-94, 1993
Fabia R et al.: Effects of phosphatidylcholine on acetic acid-induced colitis in the rat. Digestion 53: 35-44, 1992
Galli C et al.: Oral polyunsaturated phosphatidylcholine reduces platelet lipid and cholesterol contents in healthy volunteers. Lipids 20(9):561-6, 1985
Holecek M et al.: Effect of polyunsaturated phosphatidylcholine on liver regeneration onset after hepatectomy in the rat. Arzneimittelforschung 42(3): 337-39, 1992
Horejsova M and Urban J: The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings--preliminary study. Cas Lek Cesk 133(12):366-9, 1994
James OFW et al.: Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 29: 495-501, 1998
Kesaniemi YA et al.: Effects of dietary polyenylphosphatidylcholine on metabolism of cholesterol and triglycerides in hypertriglyceridemic patients. Am J Clin Nutr 43: 98-107, 1986
Kirsten R et al.: Polyenylphosphatidylcholine improves the lipoprotein profile in diabetic patients. Int J Clin Pharmacol Ther 32(2): 53-6, 1994
Klimov AN et al.: "Essential" phospholipids versus nicotinic acid in the treatment of patients with type Iib hyperlipoproteinemia and ischemic heart disease. Cardiovasc Drugs Ther 9(6):779-84, 1995
Li J et al.: Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology 15(3): 373-381, 1992
Lichtenberger LM et al.: Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Medicine 1(2): 154-58, 1995
Lieber CS et al.: Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology 12(6): 1390-98, 1990
Lieber CS et al.: Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology 106: 152-159, 1994
Lieber CS: Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)--a review. Alcohol Clin Exp Res 23(6):991-1007, 1999
Ma X et al.: Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol 24: 604-613, 1996
Navder KP et al.: Polyenylphosphatidylcholine decreases alcoholic hyperlipemia without affecting the alcohol-induced rise of HDL-cholesterol. Life Sci 61(19): 1907-14, 1997
Navder KP et al.: Oxidation of LDL in baboons is increased by alcohol and attenuated by polyenylphosphatidylcholine. J Lipid Res 40(6):983-7, 1999
Niederau C et al.: Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis B and C: A multi-center, randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 45: 797-804, 1998
Oneta CM et al.: Dilinoleoylphosphatidylcholine selectively modulateslipopolysaccharide-induced Kupffer cell activation. J Lab Clin Med 134(5):466-70, 1999
Raskin JB: Gastrointestinal effects of nonsteroidal anti-inflammatory therapy. Am J Med 106(5B), 1999
Stoffel W et al.: Pleomorphic functions of highly unsaturated phospholipids in biological membranes and serum lipoproteins. Med Welt 29(4): 124-31, 1978
Verdery RB et al.: Caloric restriction increases HDL2 levels in rhesus monkeys (Macaca mulatta). Am J Physiol 273(4 Pt 1):E714-9, 1997
Wallace LA et al.: Personal exposures, indoor-outdoor relationships and breath levels of toxic air pollutants measured for 355 persons in New Jersey. EPA 0589, 1989
Wang XD, Andersson R et al.: Phospholipids prevent enteric bacterial translocation in the early stage of experimental acute liver failure in the rat. Scand J Gastroenterol 29:1117-21, 1994
Weltman MD et al.: Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27(1): 128-133, 1998
Wolfe MM et al.: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. NEJM 340(24):1888-99, 1999
Yamada S et al.: Chronic ethanol consumption alters rat liver plasma membranes and potentiates release of alkaline phosphatase. Gastroenterology 88(6): 1799-806, 1985
Yang SQ et al.: Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94: 2557-62, 1997